Treats pseudobulbar affect (PBA). ANDA 218426, held by Hetero Labs Ltd Iii. Dextromethorphan Hydrobromide; Quinidine Sulfate.
As of Nov 16, 2026, ANDA 218426 (Dextromethorphan Hydrobromide And Quinidine Sulfate), held by Hetero Labs Ltd Iii, was first approved by FDA on Aug 28, 2024, with 0 approved supplements and 0 published complete response letters.
Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dextromethorphan Hydrobromide And Quinidine Sulfate20MG;10MG · capsule;oral | Dextromethorphan Hydrobromide; Quinidine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters